wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35634179-2E508BC6-DFA7-410C-8D13-7917FE3CFA83
Q35634179-2E508BC6-DFA7-410C-8D13-7917FE3CFA83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35634179-2E508BC6-DFA7-410C-8D13-7917FE3CFA83
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy
P2860
Q35634179-2E508BC6-DFA7-410C-8D13-7917FE3CFA83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35634179-2E508BC6-DFA7-410C-8D13-7917FE3CFA83
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f62a29b5c21548ea2edbc6b4a5fda715a9e532c7
P2860
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.